-
Posted by
Two Blokes 6 hours ago -
Filed in
Stock
-
0 views
Gene therapy stocks like CRISPR Therapeutics and Intellia Therapeutics are facing significant volatility in 2025, influenced by market instability and regulatory uncertainties. CRSP is better positioned to navigate near-term challenges with a strong cash reserve and upcoming product launches, justifying an upgrade to 'Strong Buy.' NTLA, despite promising product candidates, faces higher risks and requires significant cost reductions to extend its cash runway, maintaining a "Buy" rating for high-risk investors.
